Mizuho Initiates Coverage On Boyd Group Services with Outperform Rating, Announces Price Target of $120
Mizuho analyst David Bellinger initiates coverage on Boyd Group Services (NYSE:BGSI) with a Outperform rating and announces Price Target of $120.
Stocks · News reference
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Boyd Group Services To Buy Back And Cancel Up To ~2.78M Shares, 10% Of Float, Through September 15, 2027
Management and the Board of Directors of Boyd believe that, from time to time, the market price of its Shares does not fully reflect the underlying value of Boyd's growth profile and cash-generating capabilities.
Boyd Group Services Q2 Adj. EPS $0.80 Misses $0.97 Estimate, Sales $1.014B Miss $1.025B Estimate
Boyd Group Services (NYSE:BGSI) reported quarterly earnings of $0.80 per share which missed the analyst consensus estimate of $0.97 by 17.53 percent. This is a 12.68 percent increase over earnings of $0.71 per share
Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer
Lift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.
What's Going on With Cue Biopharma Stock on Monday?
Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.